Allegretti Lab
Email: aallegretti@mgh.harvard.edu
Call 617-726-5050
Overview
Dr. Allegretti’s research has provided key epidemiologic and clinical observations that have affected clinical practice. His work has been cited in multiple national and international clinical practice guidelines in both liver and kidney disease. This includes research around renal replacement therapy in cirrhosis, kidney function before and after transjugular intrahepatic portosystemic shunt (TIPS) placement, and outcomes around acute kidney injury and liver transplantation. His lab studies patient phenotypes to identify sources of inflammation and endothelial cell dysfunction as novel mechanisms of hepatorenal syndrome and advanced liver disease. His work at the beside has resulting in advancements in continuous renal replacement therapy, including development of novel anticoagulation strategies and delivery of accelerated venovenous hemofiltration (AVVH), also called prolonged intermittent renal replacement therapy.
Dr. Allegretti has served as lead PI and on steering committees for multiple national and international randomized clinical trials. His work has been supported by awards from the National Institutes of Health, American Heart Association, American Association for the Study of Liver Diseases, and the American College of Gastroenterology.